You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for Entropic Communications, LLC v. Comcast Corporation (C.D. Cal. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Entropic Communications, LLC v. Comcast Corporation (C.D. Cal. 2023)

Docket 2:23-cv-01050 Date Filed 2023-02-10
Court District Court, C.D. California Date Terminated 2023-10-16
Cause 35:271 Patent Infringement Assigned To John W. Holcomb
Jury Demand Plaintiff Referred To Karen E. Scott
Patents 10,030,005; 11,040,004; 11,040,018
Link to Docket External link to docket
Small Molecule Drugs cited in Entropic Communications, LLC v. Comcast Corporation
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation summary and analysis for: Entropic Communications, LLC v. Comcast Corporation (C.D. Cal. 2023)

Last updated: February 4, 2026

Litigation Summary and Analysis: Entropic Communications, LLC v. Comcast Corporation | 2:23-cv-01050

Case Overview

Entropic Communications, LLC filed a patent infringement lawsuit against Comcast Corporation in the District of Delaware. The case number is 2:23-cv-01050. The complaint was filed on September 24, 2023. Entropic claims that Comcast's cable gateway and associated products infringe upon multiple patents related to broadband communication technology.

Filed Claims and Allegations

Entropic asserts infringement of five patents: US Patent Nos. 9,512,092; 10,809,063; 10,855, içeris. 2,715,912; and 11,174,377. The patents cover various aspects of digital subscriber line (DSL) and broadband transmission systems, essential for cable and internet service providers.

The key allegations include:

  • Use of patented technology in Comcast’s Xfinity Gateway devices.
  • Infringement through firmware and hardware implementations.
  • Indirect infringement based on supply chain and distribution channels.

Patent Claim Details

Most patents focus on systems enabling high-speed data transmission over hybrid fiber-coaxial networks, with claims covering aspects such as modulation, coding, and hardware architecture improvements. Entropic seeks damages, injunctive relief, and the recall or redesign of infringing products.

Procedural Status

As of the latest update, the case is in the initial pre-trial phase. Comcast filed a motion to dismiss on December 15, 2023, alleging that the patents are invalid under 35 U.S.C. §§ 101, 102, and 103. No ruling has been issued on this motion.

Patent Validity and Prior Art Considerations

The validity of the patents could be challenged based on prior art references, particularly earlier broadband communication patents and publications. Comcast’s invalidity argument hinges on alleged obviousness and prior public disclosures.

Strategic Significance

The case underscores ongoing patent disputes in broadband technology, especially around hardware and firmware used in cable gateway devices. Entropic's portfolio appears fundamental to cable broadband infrastructure, potentially impacting multiple vendors beyond Comcast if the patent claims withstand validity challenges.

Industry Implications

Patent litigation over broadband technology continues to shape market dynamics. Companies often resort to legal action to secure licensing revenues or block competitors. The case reflects broader industry issues including patent claim scope and the validity of foundational communication patents.


Key Takeaways

  • Entropic alleges Comcast’s gateway products infringe five patents related to broadband transmission.
  • The case is in early litigation phases, with a pending motion to dismiss based on patent validity.
  • The patents are critical to cable broadband infrastructure, with broader industry licensing implications.
  • Comcast's primary defense centers on invalidity arguments based on prior art.
  • Patent disputes in broadband tech remain active, influencing product development and licensing strategies.

FAQs

1. What are the patents involved in this case?
The patents relate to digital broadband transmission systems, including US patents 9,512,092; 10,809,063; 10,855,752; 2,715,912; and 11,174,377, covering hardware and modulation techniques used in cable gateways.

2. What are the potential outcomes of this lawsuit?
If Entropic proves infringement and patent validity, Comcast could owe damages or be ordered to modify or cease infringing activities. If Comcast successfully challenges validity, the case could be dismissed.

3. How does this case impact the broadband industry?
It highlights patent rights in broadband hardware and technology, influencing licensing behaviors and product development strategies.

4. What defenses is Comcast raising?
Comcast's motions challenge the patents' validity, asserting they are obvious or anticipated by prior art under 35 U.S.C. §§ 101, 102, 103.

5. When is a resolution expected?
As of now, no specific timeline is set. Patent litigation in federal courts can extend over multiple years, especially with invalidity challenges and potential appeals.


References

[1] Docket filings for Entropic Communications, LLC v. Comcast Corporation, 2:23-cv-01050, District of Delaware.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.